Stratify Genomics was founded by a leading urologist who became concerned about the controversy surrounding PSA screening leading to delayed diagnosis and an increase in incurable disease in patients. Stratify is focused on a solution designed to curb this disturbing trend.
Stratify is dedicated to advancing the knowledge of genetic predisposition to cancer and other diseases so practitioners can screen more effectively and efficiently.
Prompt PGS is a major advancement in defining risk for prostate cancer; the test was developed, and its performance characteristics determined by Stratify Genomics in collaboration with Diagnomics. This simple germline DNA test obtained from a buccal swab that analyzes over 30 Single Nucleotide Polymorphisms (SNPs) can help identify those high-risk men who may benefit most from prostate cancer screening and possibly even stratiegies to prevent prostate cancer. Prompt PGS provides actionable results across the entire spectrum of test results helping HCPs develop personalized PSA based screening protocols as well as providing important information for biopsy desicion making.
Visit Booth # 2535J
Brands: Prompt PGS is a risk adapted screening test that has an important role
in prostate cancer screening for you and your patients.
Supported by Stratify Genomics